Drugs / meningitis conjugate vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02286895 | Oct 2014 → Mar 2015 | Rotavirus infection | PATH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | meningitis conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286895 ↗ |
| Known as | PsA-TT-5μg | “Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).” NCT02286895 ↗ |
| Modality | Vaccine | “A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT).” NCT02286895 ↗ |
| Route | Intramuscular | “This vaccine was administered intramuscularly to the right thigh.” NCT02286895 ↗ |